Aroa Biosurgery Ltd Cash Flow Conversion Efficiency
Aroa Biosurgery Ltd cash flow conversion efficiency. Based on the latest financial reports, Aroa Biosurgery Ltd (ARX) has a cash flow conversion efficiency ratio of 0.045x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$3.64 Million ≈ $2.58 Million USD) by net assets (AU$80.93 Million ≈ $57.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aroa Biosurgery Ltd (2014–2025)
Cash flow conversion efficiency of Aroa Biosurgery Ltd from 2014 to 2025. This chart illustrates how Aroa Biosurgery Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ARX share price today for real-time trading data and today's change.
Aroa Biosurgery Ltd Cash Flow Conversion Ratio Explained
Aroa Biosurgery Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aroa Biosurgery Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aroa Biosurgery Ltd ranked by their cash flow conversion efficiency. Also see Aroa Biosurgery Ltd (ARX) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Excel Industries Limited
NSE:EXCELINDUS
|
0.010x |
|
Vardhman Holdings Limited
NSE:VHL
|
0.000x |
|
PT Mandiri Herindo Adiperkasa Tbk
JK:MAHA
|
-0.050x |
|
STCube Inc
KQ:052020
|
-0.065x |
|
Annehem Fastigheter AB
ST:ANNE-B
|
0.012x |
|
Chime Ball Technology Co Ltd
TWO:1595
|
-0.018x |
|
Duksan Hi Metal Co.Ltd
KQ:077360
|
-0.001x |
|
Reit Azorim HF Living Ltd
TA:AZRT
|
-0.016x |
Annual Cash Flow Conversion Efficiency for Aroa Biosurgery Ltd (2014–2025)
The table below shows the annual cash flow conversion efficiency of Aroa Biosurgery Ltd from 2014 to 2025. Review ARX free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | AU$84.59 Million ≈ $59.85 Million |
AU$-2.33 Million ≈ $-1.65 Million |
-0.028x | +64.51% |
| 2024-03-31 | AU$87.09 Million ≈ $61.62 Million |
AU$-6.76 Million ≈ $-4.79 Million |
-0.078x | -109.81% |
| 2023-03-31 | AU$95.38 Million ≈ $67.49 Million |
AU$-3.53 Million ≈ $-2.50 Million |
-0.037x | +67.71% |
| 2022-03-31 | AU$93.40 Million ≈ $66.09 Million |
AU$-10.71 Million ≈ $-7.58 Million |
-0.115x | -22.95% |
| 2021-03-31 | AU$53.69 Million ≈ $37.99 Million |
AU$-5.01 Million ≈ $-3.54 Million |
-0.093x | -471.64% |
| 2020-03-31 | AU$62.86 Million ≈ $44.48 Million |
AU$1.58 Million ≈ $1.12 Million |
0.025x | +4523.65% |
| 2019-03-31 | AU$11.52 Million ≈ $8.15 Million |
AU$-6.54K ≈ $-4.62K |
-0.001x | +99.96% |
| 2018-03-31 | AU$1.77 Million ≈ $1.25 Million |
AU$-2.80 Million ≈ $-1.98 Million |
-1.586x | -1251.70% |
| 2017-03-31 | AU$6.28 Million ≈ $4.44 Million |
AU$-737.06K ≈ $-521.52K |
-0.117x | -70.03% |
| 2016-03-31 | AU$5.91 Million ≈ $4.18 Million |
AU$-408.04K ≈ $-288.71K |
-0.069x | +64.65% |
| 2015-03-31 | AU$6.92 Million ≈ $4.90 Million |
AU$-1.35 Million ≈ $-956.64K |
-0.195x | -8.88% |
| 2014-03-31 | AU$7.58 Million ≈ $5.36 Million |
AU$-1.36 Million ≈ $-961.75K |
-0.179x | -- |
About Aroa Biosurgery Ltd
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and co… Read more